Macrophage migration inhibitory factor ameliorates UV-induced photokeratitis in mice. 2008

Nobuyoshi Kitaichi, and Tadamichi Shimizu, and Kazuhiko Yoshida, and Ayumi Honda, and Yoko Yoshihisa, and Satoru Kase, and Kazuhiro Ohgami, and Osamu Norisugi, and Teruhiko Makino, and Jun Nishihira, and Sho-Ichi Yamagishi, and Shigeaki Ohno
Department of Ophthalmology and Visual Sciences, Hokkaido University Graduate School of Medicine, Sapporo, Japan. nobukita@med.hokudai.ac.jp

Acute ultraviolet (UV) exposure causes photokeratitis, and induces apoptosis in corneal cells of the eye. Macrophage migration inhibitory factor (MIF) was originally identified as a lymphokine. Today, MIF is considered as an integral component of the host antimicrobial alarm system and stress response that promotes the proinflammatory functions of immune cells. Also, MIF is considered to contribute the wound healing process. The aim of the present study is to determine the effects of MIF expression on UV irradiated corneal damage. MIF transgenic (MIF-Tg), wild type (WT), and MIF deficient (MIF KO) mice were UVB-irradiated of 400mJ/cm2 to induce acute UV-photokeratitis. MIF Tg mice constitutively produce high levels of MIF. Morphological changes were most severe in MIF KO mice, and WT and MIF Tg mice were following. Corneal basement membrane of MIF-Tg was well preserved. Prominent higher level of MIF was observed in MIF-Tg than WT after UVB irradiation in cornea. TUNEL staining showed a significantly smaller number of TUNEL positive nuclei in MIF-Tgm (6.2+/-4.3 cells/section, p<0.01 compared with WT) than WT (30.7+/-9.1) and MIF KO mice (32.1+/-12.7) 24h after UV exposure. The number of c-Jun positive nuclei was significantly higher in MIF Tg (p<0.01) than in WT and MIF KO mice. Serial observation revealed that BrdU incorporation was significantly upregulated in MIF Tg (p<0.01), but downregulated in MIF KO (p<0.01) than WT mice. MIF expression may thus be related to the amelioration of UVB-caused corneal injury, and this association was attributable to the upregulation of cell proliferation after acute UV-induced corneal damage, which involves the c-Jun dependent pathway. In conclusion, UV-damaged cornea is recoverable without MIF, however it takes longer time than normal condition. Cornea is less damaged and can make a quick recovery when ocular tissue is enough supplied with MIF.

UI MeSH Term Description Entries
D007634 Keratitis Inflammation of the cornea. Keratitides
D008263 Macrophage Migration-Inhibitory Factors Proteins released by sensitized LYMPHOCYTES and possibly other cells that inhibit the migration of MACROPHAGES away from the release site. The structure and chemical properties may vary with the species and type of releasing cell. Macrophage Migration Inhibitory Factor,Migration Inhibition Factors, Macrophage,Macrophage Migration Inhibition Factors,Migration Inhibition Factor, Macrophage,Macrophage Migration Inhibitory Factors,Migration-Inhibitory Factors, Macrophage
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D008822 Mice, Transgenic Laboratory mice that have been produced from a genetically manipulated EGG or EMBRYO, MAMMALIAN. Transgenic Mice,Founder Mice, Transgenic,Mouse, Founder, Transgenic,Mouse, Transgenic,Mice, Transgenic Founder,Transgenic Founder Mice,Transgenic Mouse
D010787 Photosensitivity Disorders Abnormal responses to sunlight or artificial light due to extreme reactivity of light-absorbing molecules in tissues. It refers almost exclusively to skin photosensitivity, including sunburn, reactions due to repeated prolonged exposure in the absence of photosensitizing factors, and reactions requiring photosensitizing factors such as photosensitizing agents and certain diseases. With restricted reference to skin tissue, it does not include photosensitivity of the eye to light, as in photophobia or photosensitive epilepsy. Actinic Reticuloid Syndrome,Dermatitis, Actinic,Photodermatitis,Chronic Actinic Dermatitis,Photosensitization,Actinic Dermatitides,Actinic Dermatitides, Chronic,Actinic Dermatitis,Actinic Dermatitis, Chronic,Actinic Reticuloid Syndromes,Chronic Actinic Dermatitides,Dermatitides, Actinic,Dermatitides, Chronic Actinic,Dermatitis, Chronic Actinic,Disorder, Photosensitivity,Disorders, Photosensitivity,Photodermatitides,Photosensitivity Disorder,Reticuloid Syndrome, Actinic,Reticuloid Syndromes, Actinic,Syndrome, Actinic Reticuloid,Syndromes, Actinic Reticuloid
D011833 Radiation Injuries, Experimental Experimentally produced harmful effects of ionizing or non-ionizing RADIATION in CHORDATA animals. Experimental Radiation Injuries,Injuries, Experimental Radiation,Experimental Radiation Injury,Radiation Injury, Experimental
D005136 Eye Proteins PROTEINS derived from TISSUES of the EYE. Proteins, Eye
D005786 Gene Expression Regulation Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control (induction or repression) of gene action at the level of transcription or translation. Gene Action Regulation,Regulation of Gene Expression,Expression Regulation, Gene,Regulation, Gene Action,Regulation, Gene Expression
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D012333 RNA, Messenger RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm. Messenger RNA,Messenger RNA, Polyadenylated,Poly(A) Tail,Poly(A)+ RNA,Poly(A)+ mRNA,RNA, Messenger, Polyadenylated,RNA, Polyadenylated,mRNA,mRNA, Non-Polyadenylated,mRNA, Polyadenylated,Non-Polyadenylated mRNA,Poly(A) RNA,Polyadenylated mRNA,Non Polyadenylated mRNA,Polyadenylated Messenger RNA,Polyadenylated RNA,RNA, Polyadenylated Messenger,mRNA, Non Polyadenylated

Related Publications

Nobuyoshi Kitaichi, and Tadamichi Shimizu, and Kazuhiko Yoshida, and Ayumi Honda, and Yoko Yoshihisa, and Satoru Kase, and Kazuhiro Ohgami, and Osamu Norisugi, and Teruhiko Makino, and Jun Nishihira, and Sho-Ichi Yamagishi, and Shigeaki Ohno
March 2010, PLoS pathogens,
Nobuyoshi Kitaichi, and Tadamichi Shimizu, and Kazuhiko Yoshida, and Ayumi Honda, and Yoko Yoshihisa, and Satoru Kase, and Kazuhiro Ohgami, and Osamu Norisugi, and Teruhiko Makino, and Jun Nishihira, and Sho-Ichi Yamagishi, and Shigeaki Ohno
May 2020, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
Nobuyoshi Kitaichi, and Tadamichi Shimizu, and Kazuhiko Yoshida, and Ayumi Honda, and Yoko Yoshihisa, and Satoru Kase, and Kazuhiro Ohgami, and Osamu Norisugi, and Teruhiko Makino, and Jun Nishihira, and Sho-Ichi Yamagishi, and Shigeaki Ohno
August 2004, Journal of molecular and cellular cardiology,
Nobuyoshi Kitaichi, and Tadamichi Shimizu, and Kazuhiko Yoshida, and Ayumi Honda, and Yoko Yoshihisa, and Satoru Kase, and Kazuhiro Ohgami, and Osamu Norisugi, and Teruhiko Makino, and Jun Nishihira, and Sho-Ichi Yamagishi, and Shigeaki Ohno
January 2018, Kardiologia polska,
Nobuyoshi Kitaichi, and Tadamichi Shimizu, and Kazuhiko Yoshida, and Ayumi Honda, and Yoko Yoshihisa, and Satoru Kase, and Kazuhiro Ohgami, and Osamu Norisugi, and Teruhiko Makino, and Jun Nishihira, and Sho-Ichi Yamagishi, and Shigeaki Ohno
January 2002, Critical care medicine,
Nobuyoshi Kitaichi, and Tadamichi Shimizu, and Kazuhiko Yoshida, and Ayumi Honda, and Yoko Yoshihisa, and Satoru Kase, and Kazuhiro Ohgami, and Osamu Norisugi, and Teruhiko Makino, and Jun Nishihira, and Sho-Ichi Yamagishi, and Shigeaki Ohno
April 2003, Expert opinion on therapeutic targets,
Nobuyoshi Kitaichi, and Tadamichi Shimizu, and Kazuhiko Yoshida, and Ayumi Honda, and Yoko Yoshihisa, and Satoru Kase, and Kazuhiro Ohgami, and Osamu Norisugi, and Teruhiko Makino, and Jun Nishihira, and Sho-Ichi Yamagishi, and Shigeaki Ohno
January 2002, Critical care medicine,
Nobuyoshi Kitaichi, and Tadamichi Shimizu, and Kazuhiko Yoshida, and Ayumi Honda, and Yoko Yoshihisa, and Satoru Kase, and Kazuhiro Ohgami, and Osamu Norisugi, and Teruhiko Makino, and Jun Nishihira, and Sho-Ichi Yamagishi, and Shigeaki Ohno
December 2005, Critical care medicine,
Nobuyoshi Kitaichi, and Tadamichi Shimizu, and Kazuhiko Yoshida, and Ayumi Honda, and Yoko Yoshihisa, and Satoru Kase, and Kazuhiro Ohgami, and Osamu Norisugi, and Teruhiko Makino, and Jun Nishihira, and Sho-Ichi Yamagishi, and Shigeaki Ohno
October 1983, Cellular immunology,
Nobuyoshi Kitaichi, and Tadamichi Shimizu, and Kazuhiko Yoshida, and Ayumi Honda, and Yoko Yoshihisa, and Satoru Kase, and Kazuhiro Ohgami, and Osamu Norisugi, and Teruhiko Makino, and Jun Nishihira, and Sho-Ichi Yamagishi, and Shigeaki Ohno
June 2003, European journal of immunology,
Copied contents to your clipboard!